Corrections: Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study (The Lancet Infectious Diseases (2017) (S1473309917306813) (10.1016/S1473-3099(17)30681-3));Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study

The Lancet Infectious Diseases

Volumn 18, Issue 2, 2018, Pages 188-197

  Hermans, Lucas E ^a,b,d   Moorhouse, Michelle ^b   Carmona, Sergio ^c,e   Grobbee, Diederick E ^a,d   Hofstra, L Marije ^a   Richman, Douglas D ^f   Tempelman, Hugo A ^d,g   Venter, Willem D F ^b,d   Wensing, Annemarie M J ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Ndlovu Research Consortium   (South Africa)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g NDLOVU CARE GROUP   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ANTIRETROVIRUS AGENT;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AFRICAN; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ADOLESCENT; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; SOUTH AFRICA; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 85034853518     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30685-0     Document Type: Erratum

References (30)

1. UNAIDS. Ending AIDS. Progress towards the 90-90-90 targets. Global AIDS update 2017. http://www.unaids.org/en/resources/campaigns/globalAIDSupdate2017 (accessed Oct 16, 2017).
2. WHO. WHO global health observatory (GHO) data. http://www.who.int/gho/hiv/epidemic_response/ART/en/, 2016 (accessed Oct 14, 2016).
3. Boender, TS, Sigaloff, KCE, McMahon, JH, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 61 (2015), 1453–1461.
4. Gupta, RK, Jordan, MR, Sultan, BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380 (2012), 1250–1258.
5. Rhee, SY, Blanco, JL, Jordan, MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med, 12, 2015, e1001810.
6. WHO. WHO HIV drug resistance report 2012. http://www.who.int/hiv/pub/drugresistance/report2012/en/, July 2012 (accessed Oct 16, 2017).
7. Kagee, A, Remien, R, Berkman, A, Hoffman, S, Campos, L, Swartz, L, Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health 6 (2011), 83–97.
8. Barth, RE, van der Loeff, MFS, Schuurman, R, Hoepelman, AIM, Wensing, AMJ, Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10 (2010), 155–166.
9. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/arv/arv-2016/en/, June 2016 (accessed Oct 16, 2017).
10. European AIDS Clinical Society. EACS guidelines version 8.1. http://www.eacsociety.org/files/guidelines_8.1-english.pdf, October 2016 (accessed Oct 16, 2017).
11. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf, January 2013 (accessed Oct 16, 2017).
12. Geretti, AM, Smith, C, Haberl, A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 13 (2008), 927–936.
13. Ryscavage, P, Kelly, S, Li, JZ, Harrigan, PR, Taiwo, B, Significance and clinical management of persistent low level viremia and very low level viremia in HIV-1 infected patients. Antimicrob Agents Chemother 58 (2014), 3585–3598.
14. Podsadecki, TJ, Vrijens, BC, Tousset, EP, Rode, RA, Hanna, GJ, Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 196 (2007), 1773–1778.
15. Leierer, G, Grabmeier-Pfistershammer, K, Steuer, A, et al. Factors associated with low-level viraemia and virological failure: results from the Austrian HIV cohort study. PLoS One, 10, 2015, e0142923.
16. Mackie, NE, Phillips, AN, Kaye, S, Booth, C, Geretti, A, Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis 201 (2010), 1303–1307.
17. Li, JZ, Gallien, S, Do, TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother 56 (2012), 5998–6000.
18. Swenson, LC, Min, JE, Woods, CK, et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS 28 (2014), 1125–1134.
19. Vandenhende, MA, Perrier, A, Bonnet, F, et al. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir Ther 20 (2015), 655–660.
20. Raboud, JM, Rae, S, Woods, R, et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 16 (2002), 1627–1632.
21. Sungkanuparph, S, Groger, RK, Overton, ET, Fraser, VJ, Powderly, WG, Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 7 (2006), 437–441.
22. Laprise, C, de Pokomandy, A, Baril, J-G, Dufresne, S, Trottier, H, Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 57 (2013), 1489–1496.
23. Hofstra, L, Mudrikova, T, Stam, AJ, et al. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS One, 9, 2014, e110749.
24. Antiretroviral Therapy Cohort Collaboration. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS 29 (2015), 373–383.
25. Boillat-Blanco, N, Darling, K, Schoni-Affolter, F, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. Antivir Ther 20 (2015), 165–175.
26. Ngwa, JS, Cabral, HJ, Cheng, DM, et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol, 16, 2016, 148.
27. Snapinn, S, Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat 59 (2005), 301–307.
28. Paton, NI, Kityo, C, Hoppe, A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 371 (2014), 234–247.
29. Gonzalez-Serna, A, Swenson, LC, Watson, B, et al. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infect 22 (2016), 1004.e9–1004.e16.
30. National Department of Health (South Africa). National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. https://aidsfree.usaid.gov/sites/default/files/tx_south-africa_pmtct_2015.pdf, April 2015 (accessed Oct 16, 2017).